Piramal Pharma Ltd's Q3FY25 Quarter Results
- 29 Jan 2025
Result Summary
- Piramal Pharma Ltd reported a 3.8% quarter-on-quarter (QoQ) decrease in its consolidated revenues for the quarter-ended Dec (Q3FY25). On a year-on-year (YoY) basis, it witnessed a growth of 9.7%.
- Its expenses for the quarter were down by 1.5% QoQ and up 9.3% YoY.
- The net profit decreased 83.7% QoQ and decreased 63.6% YoY.
- The earnings per share (EPS) of Piramal Pharma Ltd - at - during Q3FY25.
Financial Statments for Q3FY25
| (₹ crores) | Q3FY25 | Q2FY25 | Q3FY24 | QoQ (%) | YoY (%) |
|---|---|---|---|---|---|
Total Income | 2216.35 | 2302.86 | 2020.08 | -3.8% | 9.7% |
Total Expenses | 2166.60 | 2200.00 | 1982.40 | -1.5% | 9.3% |
Profit Before Tax | 49.75 | 102.86 | 5.41 | -51.6% | 819.6% |
Tax | 63.12 | 97.53 | 9.25 | -35.3% | 582.4% |
Profit After Tax | 3.68 | 22.59 | 10.11 | -83.7% | -63.6% |
Earnings Per Share | 0.00 | 0.20 | 0.10 | -100.0% | -100.0% |
Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results
Company Overview
Piramal Pharma Ltd is a prominent pharmaceutical company that operates in the healthcare sector. The company specializes in providing a range of pharmaceutical products and services including contract development and manufacturing, critical care, over-the-counter products, and a strong presence in the consumer products sector. Piramal Pharma is renowned for its innovative approach and extensive research and development capabilities that help in delivering high-quality pharmaceutical solutions. As of my last update, there have been no specific recent major developments publicly disclosed, although the company continues to focus on expanding its global footprint and enhancing its product portfolio to cater to diverse healthcare needs.
Revenue
During Q3FY25, Piramal Pharma Ltd reported a total income of ₹2216.35 crores. This represents a decrease of 3.8% quarter-over-quarter (QoQ) compared to ₹2302.86 crores in Q2FY25, yet it shows a year-over-year (YoY) increase of 9.7% from ₹2020.08 crores in Q3FY24. These figures indicate a robust YoY growth in revenue, despite a slight decline in comparison to the previous quarter. The overall revenue trend reflects the company's ongoing efforts to maintain a positive growth trajectory on an annual basis.
Profitability
For Q3FY25, Piramal Pharma Ltd's profit before tax was recorded at ₹49.75 crores, down by 51.6% from ₹102.86 crores in Q2FY25, but significantly higher than the ₹5.41 crores reported in Q3FY24, marking an 819.6% YoY increase. However, the profit after tax in Q3FY25 was ₹3.68 crores, which shows a substantial reduction of 83.7% QoQ from ₹22.59 crores in Q2FY25 and a 63.6% decrease YoY from ₹10.11 crores in Q3FY24. Earnings per share for Q3FY25 was recorded at ₹0.00, compared to ₹0.20 in Q2FY25 and ₹0.10 in Q3FY24, reflecting a 100.0% decrease both QoQ and YoY.
Operating Metrics
The total expenses for Piramal Pharma Ltd in Q3FY25 amounted to ₹2166.60 crores, a slight decrease of 1.5% from ₹2200.00 crores in Q2FY25, while showing a YoY increase of 9.3% from ₹1982.40 crores in Q3FY24. This data points to a steady management of operational costs, with expenses growing at a rate similar to revenue on an annual basis. The tax for the quarter was ₹63.12 crores, representing a 35.3% decrease QoQ from ₹97.53 crores in Q2FY25 and a 582.4% increase YoY from ₹9.25 crores in Q3FY24. These financial metrics give insight into the company's operational efficiency and fiscal management strategies over the comparative periods.
